DK167482A - Fremgangsmaade til fremstilling af produkter,der er anvendelige til behandling af melanomer - Google Patents

Fremgangsmaade til fremstilling af produkter,der er anvendelige til behandling af melanomer Download PDF

Info

Publication number
DK167482A
DK167482A DK167482A DK167482A DK167482A DK 167482 A DK167482 A DK 167482A DK 167482 A DK167482 A DK 167482A DK 167482 A DK167482 A DK 167482A DK 167482 A DK167482 A DK 167482A
Authority
DK
Denmark
Prior art keywords
melanomes
procedure
treatment
products used
manufacturing products
Prior art date
Application number
DK167482A
Other languages
English (en)
Other versions
DK159277C (da
DK159277B (da
Inventor
F K Jansen
P Gros
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of DK167482A publication Critical patent/DK167482A/da
Publication of DK159277B publication Critical patent/DK159277B/da
Application granted granted Critical
Publication of DK159277C publication Critical patent/DK159277C/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK167482A 1981-04-15 1982-04-14 Analogifremgangsmaade til fremstilling af produkter, der er anvendelige til behandling af melanomer DK159277C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8107596A FR2504010B1 (fr) 1981-04-15 1981-04-15 Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
FR8107596 1981-04-15

Publications (3)

Publication Number Publication Date
DK167482A true DK167482A (da) 1982-10-16
DK159277B DK159277B (da) 1990-09-24
DK159277C DK159277C (da) 1991-02-18

Family

ID=9257448

Family Applications (1)

Application Number Title Priority Date Filing Date
DK167482A DK159277C (da) 1981-04-15 1982-04-14 Analogifremgangsmaade til fremstilling af produkter, der er anvendelige til behandling af melanomer

Country Status (30)

Country Link
US (1) US4414148A (da)
EP (1) EP0063988B1 (da)
JP (1) JPS57179124A (da)
KR (1) KR880001045B1 (da)
AR (1) AR228394A1 (da)
AT (1) ATE17653T1 (da)
AU (1) AU556641B2 (da)
CA (1) CA1195248A (da)
CZ (1) CZ256482A3 (da)
DD (1) DD204849A5 (da)
DE (1) DE3268752D1 (da)
DK (1) DK159277C (da)
EG (1) EG15718A (da)
ES (1) ES511433A0 (da)
FI (1) FI76693C (da)
FR (1) FR2504010B1 (da)
GR (1) GR69199B (da)
HU (1) HU188314B (da)
IE (1) IE53009B1 (da)
IL (1) IL65441A0 (da)
MA (1) MA19429A1 (da)
NO (1) NO154905C (da)
NZ (1) NZ200302A (da)
OA (1) OA07069A (da)
PH (1) PH20846A (da)
PL (1) PL135800B1 (da)
PT (1) PT74741B (da)
SU (1) SU1329604A3 (da)
YU (1) YU83082A (da)
ZA (1) ZA822528B (da)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
FR2523445A1 (fr) * 1982-03-17 1983-09-23 Sanofi Sa Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
IT1203672B (it) * 1982-05-12 1989-02-15 Harvard College Proteina ibrida comprendente frammenti proteici collegati da legami peptidici e relativo gene di fusione composizione contenente tale proteina
US4520226A (en) * 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
JPS5990052A (ja) * 1982-11-16 1984-05-24 Katsu Taniguchi モノクロ−ナル特異抗体を用いたメラノ−マ診断薬
US4916213A (en) * 1983-02-22 1990-04-10 Xoma Corporation Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
US4591572A (en) * 1983-04-01 1986-05-27 Sloan-Kettering Institute For Cancer Research Pigmentation associated, differentiation antigen of human melanoma and autologous antibody
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
GB2142428A (en) * 1983-06-23 1985-01-16 Erba Farmitalia Adenocarcinoma related antigenic determinants and antibodies specific thereto
FR2547731A1 (fr) * 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
FR2570278B1 (fr) * 1984-09-14 1987-02-13 Pasteur Institut Compositions et procede pour proteger les lymphocytes t contre l'agent etiologique des lymphadenopathies et du syndrome d'immunodepression acquise
EP0232447A1 (en) * 1986-02-13 1987-08-19 Xoma Corporation Lectin immunotoxins
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
AU585940B2 (en) * 1984-09-25 1989-06-29 Xoma Corporation Lectin immunotoxins
FR2573656B1 (fr) * 1984-11-29 1987-02-27 Sanofi Sa Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
US4851510A (en) * 1984-11-30 1989-07-25 Wadley Technologies, Inc. Monoclonal antibodies to novel melanoma-associated antigens
US5256413A (en) * 1985-01-08 1993-10-26 The General Hospital Corporation Method and use for site-specific activation of substances
AT384549B (de) * 1985-01-08 1987-11-25 Strasser Engelbert Verfahren zur herstellung einer vaccine
FR2577135B1 (fr) * 1985-02-13 1989-12-15 Sanofi Sa Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques
US4744981A (en) * 1985-10-17 1988-05-17 Neorx Corporation Trichothecene antibody conjugates
DE3688137D1 (de) * 1985-11-29 1993-04-29 Consolidated Pharmaceuticals L Ricin-antikoerper-konjugate.
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
US4689401A (en) * 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
USRE38008E1 (en) 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5009995A (en) * 1986-10-27 1991-04-23 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to melanoma cells
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5252713A (en) * 1988-09-23 1993-10-12 Neorx Corporation Polymeric carriers for non-covalent drug conjugation
US5171563A (en) * 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
IE20000918A1 (en) * 1990-03-22 2001-05-30 Sloan Kettering Inst Cancer GP75 As a Tumor Vaccine for Melanoma
ZA912490B (en) * 1990-04-19 1992-12-30 Res Dev Foundation Antibody conjugates for treatment of neoplastic disease
US5981194A (en) * 1992-07-10 1999-11-09 University Of British Columbia Use of p97 and iron binding proteins as diagnostic and therapeutic agents
US5690935A (en) * 1995-01-13 1997-11-25 Regents Of The University Of Minnesota Biotherapy of cancer by targeting TP-3/P80
ATE483733T1 (de) 1995-06-14 2010-10-15 Univ California Hochaffine humane antikörper gegen tumorantigene
US20030017147A1 (en) * 1996-09-20 2003-01-23 Guy L Reed Composition and method for enhancing fibrinolysis
US6869604B1 (en) * 1998-03-27 2005-03-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant anti-tumor RNAse
PT1075277E (pt) * 1998-05-08 2009-05-08 Univ California Métodos para detectar e inibir a angiogénese
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
EP2085781B2 (en) 2000-10-06 2020-03-11 Life Technologies Corporation Transfectable micelles containing semiconductor nanocrystals
US20050059031A1 (en) 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
AU2002230524A1 (en) 2000-11-16 2002-05-27 California Institute Of Technology Apparatus and methods for conducting assays and high throughput screening
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
WO2002100172A1 (en) * 2001-06-11 2002-12-19 Xenoport, Inc. Administration of agents via the pept-2 transporter
NZ530582A (en) 2001-07-17 2008-06-30 Res Dev Foundation Therapeutic agents comprising pro-apoptotic proteins, including granzyme, bax and TNF
EP2360234B1 (en) 2001-11-30 2015-07-22 Fluidigm Corporation Microfluidic device and methods of using same
US20030158254A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
US20030158089A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Administrative agents via the SMVT transporter
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US20030228619A1 (en) * 2002-06-10 2003-12-11 Xenoport, Inc. Peptide nucleic acids as tags in encoded libraries
CA2488858A1 (en) * 2002-06-12 2003-12-24 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
MXPA05000778A (es) 2002-07-18 2005-08-29 Helix Biopharma Corp Uso de ureasa para inhibir el crecimiento de celulas cancerosas.
US20040161424A1 (en) * 2002-10-08 2004-08-19 Xenoport Human organic solute transporters
US7666361B2 (en) 2003-04-03 2010-02-23 Fluidigm Corporation Microfluidic devices and methods of using same
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
AU2005306576A1 (en) * 2004-11-16 2006-05-26 Sienna Cancer Diagnostics Ltd Methods of detecting an analyte in a sample
EP2284191A3 (en) 2004-12-22 2011-07-20 Ambrx, Inc. Process for the preparation of hGH
WO2006068802A2 (en) * 2004-12-22 2006-06-29 Ambrx, Inc. COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
MX2007007590A (es) 2004-12-22 2007-12-10 Ambrx Inc Composiciones que contienen, metodos que involucran y usos de aminoacidos no naturales y polipeptidos.
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
WO2006071840A2 (en) * 2004-12-22 2006-07-06 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
US20060171919A1 (en) * 2005-02-01 2006-08-03 Research Development Foundation Targeted polypeptides
EP2371453A1 (en) 2005-03-18 2011-10-05 Fluidigm Corporation Microfluidic device
CA2609205A1 (en) * 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
WO2007021297A1 (en) * 2005-08-18 2007-02-22 Ambrx, Inc. COMPOSITIONS OF tRNA AND USES THEREOF
HRP20110404T1 (hr) * 2005-11-08 2011-08-31 Ambrx Ubrzivači za modifikaciju ne-prirodnih aminokiselina i polipeptida ne-prirodnih aminokiselina
US20090018029A1 (en) * 2005-11-16 2009-01-15 Ambrx, Inc. Methods and Compositions Comprising Non-Natural Amino Acids
ES2529065T3 (es) * 2005-12-14 2015-02-16 Ambrx, Inc. Composiciones que contienen, procedimientos que implican y usos de aminoácidos no naturales y polipéptidos
DK2064333T3 (da) * 2006-09-08 2014-05-05 Ambrx Inc Suppressor-trna-transkription i hvirveldyrceller
PT2061878E (pt) * 2006-09-08 2014-04-22 Ambrx Inc Supressor híbrido arnt para células de vertebrados
DK2615108T3 (da) 2006-09-08 2017-01-30 Ambrx Inc Modificeret humant plasmapolypeptid eller fc scaffolds og deres anvendelser
US8354110B2 (en) * 2007-03-07 2013-01-15 Uti Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions
PL2068909T3 (pl) 2007-03-30 2012-09-28 Ambrx Inc Modyfikowane polipeptydy fgf-21 i ich zastosowanie
EP2076533B1 (en) * 2007-05-02 2014-10-08 Ambrx, Inc. Modified interferon beta polypeptides and their uses
EP2192922A4 (en) 2007-09-17 2010-09-29 Univ California INTERNATIONALIZING HUMAN MONOCLONAL ANTIBODIES TO PROMOTE IN SITU ON PROSTATAZELLES
CN101868246A (zh) 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
IL198123A0 (en) 2008-04-18 2009-12-24 Snecma Propulsion Solide A heat treatment oven with inductive heating
EP2599793A1 (en) 2008-05-29 2013-06-05 Nuclea Biotechnologies, Inc. Anti-phospho-akt antibodies
PL2318029T3 (pl) * 2008-07-23 2018-03-30 Elanco Us Inc. Zmodyfikowane polipeptydy bydlęcego G-CSF i ich zastosowania
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
CA2738033C (en) * 2008-09-26 2019-11-26 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
ES2626327T3 (es) 2009-02-06 2017-07-24 The Regents Of The University Of California Agentes enlazantes de calcio que inducen crecimiento del cabello y/o crecimiento de las uñas
BR112012015461A2 (pt) 2009-12-21 2017-01-10 Ambrx Inc polipeptídeos de somatotropina boviina modificados e seus usos
US20120283172A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
EP3572091B1 (en) 2010-08-17 2023-12-13 Ambrx, Inc. Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MX354016B (es) 2010-09-15 2018-02-07 J Mrsny Randall Sistemas y metodos de suministro de agentes bioactivos mediante el uso de secuencias transportadoras derivadas de toxinas.
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
PT2621523T (pt) 2010-09-29 2017-11-15 Uti Lp Métodos para tratar doença autoimune utilizando nanoesferas bioabsorvíveis biocompatíveis
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
CN105388287A (zh) 2011-03-11 2016-03-09 内布拉斯加大学董事委员会 冠状动脉疾病的生物标志物
DK2694095T3 (da) 2011-04-05 2018-05-28 Longevity Biotech Inc Sammensætninger omfattende glucagon-analoger og fremgangsmåder til fremstilling og anvendelse af samme
KR102179369B1 (ko) 2011-05-27 2020-11-16 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
EP2714685B1 (en) 2011-05-27 2016-10-19 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
IN2014DN08236A (da) 2012-03-03 2015-05-15 Immungene Inc
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
KR102143664B1 (ko) 2012-06-07 2020-08-11 암브룩스, 인코포레이티드 전립선 특이적 막 항원 항체 약물 접합체
CA2876706A1 (en) 2012-06-14 2013-12-19 Ambrx, Inc. Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
SG11201408494UA (en) 2012-06-19 2015-02-27 Ambrx Inc Anti-cd70 antibody drug conjugates
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
AU2014252666B2 (en) 2013-04-08 2017-02-02 Helix Biopharma Corp. Use of antibody-urease conjugates for diagnostic and therapeutic purposes
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
WO2015066543A1 (en) 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
PT3065771T (pt) 2013-11-04 2019-06-24 Uti Lp Metodos e composicoes para imunoterapia prolongada
FR3018526B1 (fr) 2014-03-14 2021-06-11 Herakles Installation de densification cvi comprenant une zone de prechauffage a forte capacite
EP3139965B1 (en) 2014-05-07 2021-09-29 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
CN107108710B (zh) 2014-10-24 2022-02-15 百时美施贵宝公司 修饰的fgf-21多肽及其用途
AU2016275312B2 (en) 2015-05-06 2021-12-23 Uti Limited Partnership Nanoparticle compositions for sustained therapy
WO2017079272A2 (en) 2015-11-03 2017-05-11 Ambrx, Inc. Anti-cd3-folate conjugates and their uses
US10946106B2 (en) 2015-11-30 2021-03-16 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
CA3020601A1 (en) 2016-04-12 2017-10-19 Blaze Bioscience, Inc. Methods of treatment using chlorotoxin conjugates
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
EP3538551A4 (en) 2016-11-10 2020-11-11 Fortis Therapeutics, Inc. CD46 SPECIFIC EFFECTOR CELLS AND USES THEREOF
CA3043277A1 (en) 2016-11-11 2018-05-17 The Regents Of The University Of California Anti-cd46 antibodies and methods of use
CN110291205A (zh) 2016-12-12 2019-09-27 塞弗德公司 自动反应盒中的整合的免疫pcr和核酸分析
MX2019008056A (es) 2017-01-05 2019-11-21 Univ California Agonistas del receptor pac1 (maxcaps) y usos de estos.
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
AU2018374569B2 (en) 2017-11-29 2024-10-17 Uti Limited Partnership Methods of treating autoimmune disease
KR20250174998A (ko) 2018-03-08 2025-12-15 어플라이드 몰레큘라 트랜스포트 인크. 경구 전달용 독소-유래 전달 구조체
AU2019230230B2 (en) 2018-03-08 2025-04-10 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
US12059473B2 (en) 2018-03-29 2024-08-13 Ambrx, Inc. Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugates
US12377294B2 (en) 2018-08-28 2025-08-05 Ambrx, Inc. Anti-CD3 antibody folate bioconjugates and their uses
DK3849614T3 (da) 2018-09-11 2024-02-26 Ambrx Inc Interleukin-2-polypeptidkonjugater og anvendelser deraf
WO2020082057A1 (en) 2018-10-19 2020-04-23 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
AU2020223031B2 (en) 2019-02-12 2024-08-29 Ambrx, Inc. Compositions containing, methods and uses of antibody-TLR agonist conjugates
CA3150859A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
MX2022011163A (es) 2020-03-11 2022-10-18 Ambrx Inc Conjugados de polipeptidos de interleucina-2 y sus usos.
US11484604B2 (en) 2020-08-07 2022-11-01 Fortis Therapeutics, Inc. Immunoconjugates targeting CD46 and methods of use thereof
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
EP4313163A1 (en) 2021-04-03 2024-02-07 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
CN120344270A (zh) 2022-10-07 2025-07-18 Ambrx 公司 药物接头及其抗体缀合物
KR20250134670A (ko) 2023-01-16 2025-09-11 암브룩스, 인코포레이티드 항-cd70 항체-약물 접합체
WO2024178310A1 (en) 2023-02-23 2024-08-29 Ambrx, Inc. Trop2-directed antibody-drug conjugates and uses thereof
WO2025041055A1 (en) 2023-08-22 2025-02-27 Ambrx, Inc. Anti-psma adc conjugate compositions and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
FR2466252A2 (fr) * 1979-10-03 1981-04-10 Clin Midy Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine

Also Published As

Publication number Publication date
FR2504010B1 (fr) 1985-10-25
IL65441A0 (en) 1982-07-30
IE53009B1 (en) 1988-05-11
ES8303918A1 (es) 1983-02-16
NO154905C (no) 1987-01-14
ATE17653T1 (de) 1986-02-15
EG15718A (en) 1986-09-30
YU83082A (en) 1985-03-20
PL135800B1 (en) 1985-12-31
ZA822528B (en) 1983-02-23
PT74741A (fr) 1982-05-01
FI76693B (fi) 1988-08-31
GR69199B (da) 1982-05-06
NZ200302A (en) 1985-03-20
PH20846A (en) 1987-05-08
FI76693C (fi) 1988-12-12
NO821198L (no) 1982-10-18
PT74741B (fr) 1983-11-09
CA1195248A (en) 1985-10-15
CZ256482A3 (en) 1994-01-19
PL235981A1 (da) 1982-10-25
EP0063988A1 (fr) 1982-11-03
US4414148A (en) 1983-11-08
IE820815L (en) 1982-10-15
DD204849A5 (de) 1983-12-14
NO154905B (no) 1986-10-06
FI821304A0 (fi) 1982-04-14
KR880001045B1 (ko) 1988-06-18
DK159277C (da) 1991-02-18
MA19429A1 (fr) 1982-12-31
DK159277B (da) 1990-09-24
DE3268752D1 (en) 1986-03-13
OA07069A (fr) 1984-01-31
SU1329604A3 (ru) 1987-08-07
AU8251082A (en) 1983-04-21
KR830009777A (ko) 1983-12-23
FI821304L (fi) 1982-10-16
AR228394A1 (es) 1983-02-28
FR2504010A1 (fr) 1982-10-22
HU188314B (en) 1986-04-28
AU556641B2 (en) 1986-11-13
JPS57179124A (en) 1982-11-04
ES511433A0 (es) 1983-02-16
EP0063988B1 (fr) 1986-01-29

Similar Documents

Publication Publication Date Title
DK167482A (da) Fremgangsmaade til fremstilling af produkter,der er anvendelige til behandling af melanomer
NO822722L (no) Fremgangsmaate til fremstilling av benzazepin-2-oner.
DK260682A (da) Fremgangsmaade til fremstilling af partikelformige geler
DK149949C (da) Analogifremgangsmaade til fremstilling af n-aryl-piperazinalkanamider
DK528982A (da) Fremgangsmaade til fremstilling af 13,14-didehydro-prostaglandiner
DK31282A (da) Fremgangsmaade til fremstilling af aromatiske urethaner
DK57480A (da) Fremgangsmaade til fremstilling af insulinderivater
DK430382A (da) Fremgangsmaade til fremstilling af sukkerketaler
NO823327L (no) Fremgangsmaate for fremstilling av polymere produkter.
DK276582A (da) Fremgangsmaade til fremstilling af cephemderivater
DK153282A (da) Fremgangsmaade til fremstilling af bismethinisoindoliner
ES512519A0 (es) Proceso de fabricacion de los nuevos derivados de la amidinopiperadina.
DK353781A (da) Fremgangsmaade til fremstilling af insulinderivater
DK239382A (da) Fremgangsmaade til fremstilling af anthracyclinglycosider
DK335882A (da) Fremgangsmaade til fremstilling af cephemderivater
DK305982A (da) Fremgangsmaade til fremstilling af amidobenzamider
NO823884L (no) Fremgangsmaate til fremstilling av 1,2-dikloretan
NO814047L (no) Fremgangsmaate til fremstilling av 1,2-dikloretan
NO163061C (no) Fremgangsmaate til fremstilling av ferromangan.
DK113483D0 (da) Fremgangsmade til fremstilling af 3,4-diphenyl-5-methylpyrazolderivater
DK554982A (da) Fremgangsmaade til fremstilling af vicinalt dihalogenerede produkter
NO157422C (no) Fremgangsmaate til fremstilling av anti-t-lymfocytt-globulin.
NO811038L (no) Fremgangsmaate til fremstilling av insulin.
NO159268C (no) Fremgangsmaate for fremstilling av 3-pikolin.
DK84682A (da) Fremgangsmaade til fremstilling af trykte,flerfalsede produkter

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed